Company Description
Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States.
The company is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with relapsed and refractory leukemia and lymphoid malignancies, as well as solid tumors and non-Hodgkin lymphoma; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat advanced or metastatic solid tumors.
Its product candidates also include VIP943 in Phase 1 clinical trials for the treatment of relapsed/refractory acute myeloid leukemia, myelodysplastic syndrome, and B-cell acute lymphoblastic leukemia; and VIP924 in preclinical studies for the treatment of B-cell malignancies.
Vincerx Pharma, Inc. was founded in 2019 and is based in Palo Alto, California.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 42 |
| CEO | Dr. Ahmed M. Hamdy M.D. |
Contact Details
Address: 260 Sheridan Avenue, Suite 400 Palo Alto, California 94306 United States | |
| Phone | 650-800-6676 |
| Website | vincerx.com |
Stock Details
| Ticker Symbol | VINC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001796129 |
| CUSIP Number | 92731L106 |
| ISIN Number | US92731L1061 |
| Employer ID | 83-3197402 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ahmed M. Hamdy M.D. | Co-Founder, Chairman and Chief Executive Officer |
| Dr. Raquel E. Izumi Ph.D. | Co-Founder, President, Chief Operating Officer, Secretary and Director |
| Alexander A. Seelenberger M.B.A. | Chief Financial Officer |
| Tom C. Thomas J.D. | Founder, General Counsel and Chief Legal Officer |
| Dr. John C. Byrd M.D. | Founder and Chairman of Scientific Advisory Board |
| Dr. Hans-Georg Lerchen Ph.D. | Chief Scientific Officer |
| Gabriela Jairala | Sr Executive Director of Investor Relations and Corporate Communications |
| Karen Quarford | Vice President of Quality Operations and Compliance |
| Melissa Merrick SPHR | Senior Director of People and Culture and Head of Human Resource |
| Dr. Beatrix Stelte-Ludwig Ph.D. | Executive Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 8, 2024 | DEF 14A | Other definitive proxy statements |
| Jun 28, 2024 | PRE 14A | Other preliminary proxy statements |
| Jun 21, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 28, 2024 | 8-K | Current Report |
| May 14, 2024 | 10-Q | Quarterly Report |
| May 14, 2024 | 8-K | Current Report |
| May 3, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Apr 29, 2024 | 424B5 | Filing |
| Apr 26, 2024 | 8-K | Current Report |
| Apr 25, 2024 | 8-K | Current Report |